You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

53 Results
Guidelines and Advice
Status: Current
ID: GL-C50-24
Version: 3
Jan 2024
Drug
Other Name(s): Neulasta® , Lapelga™ , Fulphila™ , Ziextenzo® , Nyvepria™
Dec 2022
Drug
Feb 2024
Drug
Other Name(s): Perjeta®
Sep 2022
Regimen
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Sarcoma, 
Kaposi's Sarcoma
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Jan 2024
Regimen
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
May 2024

Pages